Navigation Links
Oil palm plantations are no substitute for tropical rainforests, a new study shows
Date:9/15/2008

The continued expansion of oil palm plantations will worsen the dual environmental crises of climate change and biodiversity loss, unless rainforests are better protected, warn scientists in the most comprehensive review of the subject to date.

Lead author, Emily Fitzherbert from the Zoological Society of London and University of East Anglia said: "There has been much debate over the role of palm oil production in tropical deforestation and its impacts on biodiversity. We wanted to put the discussion on a firm scientific footing."

Palm oil, used in food, cosmetics, biofuels and other products, is now the world's leading vegetable oil. It is derived from the fruit of the oil palm, grown on more than 50,000-square miles of moist, tropical lowland areas, mostly in Malaysia and Indonesia. These areas, once covered in tropical rainforest, the globe's richest wildlife habitat on land, are also home to some of the most threatened species on earth.

The review, published today in the journal Trends in Ecology and Evolution, singles out deforestation associated with plantation development as by far the biggest ecological impact, but finds that the links between the two are often much more complex than portrayed in the popular press.

Co-author Matt Struebig, from Queen Mary, University of London, explains: "Most land-cover statistics do not allow us to distinguish where oil palm has actually driven forest clearance. Oil palm certainly has directly replaced tropical forest in some areas, but oil palm companies also often have close links with timber or paper pulp companies, giving additional motives for deforestation."

Within countries, oil palm is usually grown in a few productive areas, but it looks set to spread further. Demand is increasing rapidly and 'its potential as a future agent of deforestation is enormous', the study says.

Most of the suitable land left is within the last remaining large areas of trop
'/>"/>

Contact: Sian Halkyard
s.halkyard@qmul.ac.uk
07-970-096-175
Queen Mary, University of London
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures
2. New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
3. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
4. Germicidal UVC Lights Improve Clinical Pregnancy Rates for IVF Lab, New Study Finds
5. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
8. RainDance and Scripps to Collaborate on Targeted Sequencing for Wellderly Study
9. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/19/2014)... The Latin American hardware encryption display market ... with analysis and forecast of revenue. This market was ... to reach $2,366.8 million by 2018, at a CAGR ... the TOC of the Latin American hardware encryption market ... provided. It also provides a glimpse of the segmentation ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... Paris: FR0005175080) announces promising preliminary data from,the Phase ... an adjunct to first line chemotherapy in patients ... on-going trial is a randomized, open label and ... in combination with cisplatin and,gemcitabine compared to the ...
... BRIDGEWATER, New Jersey and BIRMINGHAM, Alabama,Jan. 10 ... a,leading international scientific and regulatory consulting firm with,specialized ... Food &,Nutrition, Chemicals and Agriculture, Biotech & Consumer ... the new name for their,Pharmaceutical & Healthcare Division., ...
... Essilor,of America, Essilor International,s US subsidiary, has strengthened ... the acquisition,of Interstate Optical Co., one of the ... Mansfield, Ohio and,Indianapolis, Indiana serve eye care professionals ... US$26 million and 210 employees., Present for ...
Cached Biology Technology:Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 2Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 3Cantox Announces the Launch of Ashuren Health Sciences Pharmaceutical Division 2
(Date:10/15/2014)... German Gauß-Allianz has admitted Johannes Gutenberg University Mainz ... Rhineland-Palatinate science hub continues to maintain a significant ... , "The acceptance of Johannes Gutenberg University ... is a milestone in the national and international ... The state of Rhineland-Palatinate can be proud that ...
(Date:10/15/2014)... SHELTON, Conn. , Oct. 15, 2014 NXT-ID, Inc. ... a biometric authentication company focused on the growing mobile commerce market ... NASDAQ MarketSite in Times Square on Monday October 13 th . ... with CTO David Tunnel and angel investor Mr. ... Gino Pereira , CEO of NXT-ID thanked his investors and employees ...
(Date:10/14/2014)... discriminating thieves, prostate cancer tumors scavenge and hoard copper ... such avarice may be a fatal weakness. , ... kill prostate cancer cells by delivering a trove of ... diseased cells brimming with the mineral, leaving non-cancer cells ... already commercially available for other uses, could soon be ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Prostate cancer's penchant for copper may be a fatal flaw 2
... exposure, serving size and parental behavior are the key drivers ... discussion at the 2013 Institute of Food Technologists (IFT) Annual ... standing-room only crowd of more than 200 conference attendees heard ... what their eating behaviors are and how the industry and ...
... approved to treat multiple sclerosis may also hold promise for ... that often leads to heart failure, researchers at the University ... findings are published in the July 16 issue of ... thickening of the heart muscle that shrinks the interior ...
... have taken part in an international study which has revealed ... in one of the most hostile environments on earth. ... Tibetan plateau, the largest high-altitude land mass in the world. ... genome which reveal how it copes with the extreme living ...
Cached Biology News:Taste rules for kids and healthy food choices 2MS drug shows promise for preventing heart failure 2Genetic secrets of the world's toughest little bird 2Genetic secrets of the world's toughest little bird 3
...
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Acetyl CoA Carboxylase Antibody...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Biology Products: